“Global Acute Myeloid Leukaemia market set to grow to $2.8bn by 2022” says new Visiongain report

21 September 2018
Pharma

Visiongain has launched a new pharma report: Global Acute Myeloid Leukaemia Market Report : Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.

Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults and among the most lethal. In the United States, the annual incidence of AML is 19 000 new cases, and the incidence of AML-associated deaths is 10 000.

The rapid increase in geriatric population is one of the major drivers for the acute myeloid leukaemia market. With age, patients become highly susceptible to diseases due to decreased immunity and degeneration. As per an article published by NCBI, Acute myeloid leukaemia (AML) is the common form of acute leukaemia in adults, accounting for over 80% of all acute leukaemia in those over the age of 18 years.

The lead analyst of the report commented "The growth of the acute myeloid leukaemia market is estimated to be catalysed by opportunities in emerging markets due to improving healthcare infrastructure, unmet healthcare needs, rise in chronic diseases, and increased awareness of treatment methods.

There is a need for better therapeutics and treatment options. The increasing incidence and lack of better treatment options pose a lucrative opportunity for the market to grow and expand."

Leading companies featured in the report include Bristol-Myers Squibb Company, Celgene, Clavis Pharma ASA, Daiichi Sankyo, Eisai, GSK, Novartis, Roche, Sunesis Pharmaceuticals, Teva

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Visiongain Publishes Deep Frozen Packaging Logistics Market Report 2022-2032

The desire for various types of medications to assist combat a growing number of chronic diseases & lifestyle-related ailments is fuelling the overall deep freeze packaging logistics market demand.

14 January 2022

Read

Visiongain Publishes Pre-Filled Syringes Market Report 2022-2032

With COVID-19 pandemic, the prefilled syringes business has witnessed a significant growth. Since the outbreak of the pandemic, global market players involved in the development of the prefilled syringes market across the globe have increased their investment in raw materials and resources owing to the rise in demand for home based healthcare services.

11 January 2022

Read

Visiongain Publishes Single-use Bioprocessing Probes & Sensors Market Report 2022-2032

To promote their organic revenue growth and market presence, the top companies are pursuing different strategic initiatives such as OEM collaborations and new product development with better technological intricacy.

05 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever